Table 2.

Summary of baseline genomic alterations in patients with valid tissue NGS result^a and by suboptimal^b tumor response to treatment or not

Gene/mutation, n (%)	All evaluable (N = 104)	Suboptimalb responder (n = 23)	Not suboptimalb responder (n = 81)
TP53 any known/likely	64 (62)	15 (65)	49 (60)
TP53 frameshift/truncation	26 (25)	2 (9)	24 (30)
TP53 splice	9 (9)	2 (9)	7 (9)
TP53 missense	28 (27)	11 (48)	17 (21)
TP53 homozygous deletion	1 (1)	0	1 (1)
EGFR amplification	21 (20)	7 (30)	14 (17)
RB1 any known/likely	12 (12)	4 (17)	8 (10)
RBM10 truncation/splice	5 (5)	4 (17)	1 (1)
SMARCA4 missense/truncation	3 (3)	3 (13)	0
RICTOR amplification	3 (3)	3 (13)	0
HER2 amplification/missense	3 (3)	3 (13)	0
MET amplification	3 (3)	2 (9)	1 (1)
AKT2 any known/likely	2 (2)	2 (9)	0
CDK6 any known/likely	2 (2)	2 (9)	0
FGF23 any known/likely	2 (2)	2 (9)	0
BRCA2 any known/likely	2 (2)	2 (9)	0
APC any known/likely	6 (6)	3 (13)	3 (4)

EGFR epidermal growth factor receptor.

^aKnown/likely refers to alterations either known or likely to have a functional impact on a given protein, as determined by the algorithm described in Carr et al.⁴⁹.

^bPatients whose tumors had a suboptimal response were defined by either a best overall response of stable disease or progressive disease with a PFS of <6 months, or non-clearance of plasma ctDNA measured by ddPCR at 6 weeks.